Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Concomitant Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

NCT06841705 is registered in ClinicalTrials.gov with Shilpa Grover, MD, MPH as lead sponsor.

NCT NCT06841705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06841705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Concomitant Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Lead sponsor
Shilpa Grover, MD, MPH
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2025
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitor-related colitis